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To understand epidermal growth factor receptor (EGFR) and KRAS alterations among tissues of lung cancer patients in 
Taiwan, and to further understand how they are related, we used tumor tissues from the non-small cell lung cancer 
patients and performed a complete analysis. In the experimental results, coexisting EGFR and KRAS mutations were 
found in 1% (2/180) of the samples. This shows that these mutations tend not to coexist. Furthermore, nearly no 
coexistence was found between KRAS mutations and EGFR overexpression. These outcomes greatly assist the efficacy 
prediction of current anti-EGFR drugs for cancer patients.
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Introduction
Lung cancer is the leading cause of cancer-related 
death worldwide. In the past 40 years, the survival 
rate of this malignant disease has only minimally 
improved.1 Current knowledge on the carcinogenesis 
of lung cancer is still limited. Consequently, the pre-
vention and treatment of this disease is still limited. 
Speedy progress has been made in recent years 
using anti-epidermal growth factor receptor (EGFR) 
monoclonal antibodies or small-molecule drugs 
as a therapeutic target drugs for lung cancer.2−4 
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The probing of EGFR pathways and related down-
stream molecules is, therefore, extremely important.
EGFR is a 170-kDa transmembrane glycoprotein 
composed of an intracellular tyrosine kinase do-
main, a transmembrane lipophilic segment, and an 
extracellular ligand-binding domain. EGFR is known 
to initiate intracellular signaling pathways, trigger-
ing a cascade of well-identified molecular events 
that protect cancer cells from apoptosis, facilitate 
invasion, inhibit DNA repair, and promote angio-
genesis.5,6 Therefore, research has examined EGFR 
and related molecules in the downstream pathway. 
These include KRAS and BRAF proteins, found in 
many tumors as different variations.7−10 However, 
research reports examining non-small cell lung car-
cinoma (NSCLC) have found that the mutation rate 
of EGFR and KRAS varies by more than 40%,11,12 de-
pending on race and region. In 2008, Tang et al13 
showed that 24 primary tumors expressed EGFR 
mutations, as assessed in 50 formalin-fixed lung 
adenocarcinomas. In 2009, however, Uhara et al14 
reported that in the tumor tissues of NSCLC pa-
tients in Japan, only nine cases of 66 specimens 
were found to have a somatic mutation in EGFR. 
Furthermore, EGFR overexpression was considered 
to be a prognostic marker for colorectal cancer15 
and is related to tumor aggressiveness; however, this 
finding was not reproduced when examining human 
melanoma.16
EGFR and KRAS alterations appear to be related 
both to the formation of tumors and to the resis-
tance of cetuximab, an anti-EGFR medication.17,18 
Spano et al19 showed that the mutation of KRAS 
and EGFR in aggressive cancer cells may be related 
to the resistance of EGFR tyrosine kinase inhibitor 
medication. By analyzing EGFR and KRAS mutations, 
Kosaka et al20 suggested that both mutations are 
strictly mutually exclusive, despite contrasting re-
ports from other published work. To the authors’ 
knowledge, no published work has outlined a com-
plete analysis of the correlation between KRAS and 
EGFR mutations (or overexpression), and the clinical 
manifestations of cancer patients.
To understand EGFR and KRAS alterations among 
the tissues of lung cancer patients in Taiwan and 
to further discuss the association between the co-
existence of the two, we used tumor tissues col-
lected from NSCLC patients and performed a 
complete analysis on the proportion of EGFR over-
expression and mutation in the tissue. An inte-
grated statistical analysis was then carried out, 
taking into account clinical manifestations. This 
research aimed to help understand the role of 
EGFR and KRAS in the development of lung cancer 
in Taiwan, and to aid the development of new 
strategies to target lung adenocarcinoma using 
EGFR inhibitors.
Materials and Methods
Patients and specimen collection
The study was approved by the institutional review 
boards at Fooyin University Hospital, Pingtung 
Christian Hospital, and Kaohsiung Medical University 
Hospital. Seventy-two patients of pathology-proven 
NSCLC who had undergone surgical resection or bi-
opsy between January 2006 and December 2007 
were enrolled in this study. Written informed con-
sent was obtained from all subjects prior to sam-
ple collection. At individual hospitals, cancer and 
paired adjacent normal tissues were surgically 
obtained from 180 patients with pathology-proven 
NSCLC. The clinical pathologic records of these 
patients included sex, age, depth of invasion, tumor 
size, and lymph node metastasis. All samples were 
collected immediately after surgical resection, 
frozen instantly in liquid nitrogen, and then stored 
in a freezer at −80ºC until analysis.
DNA extraction
Genomic DNA was isolated from the surgically re-
moved tumor tissues using a proteinase-K (Stratagene, 
La Jolla, CA, USA) digestion and phenol/chloroform 
extraction procedure, according to the method out-
lined by Sambrook et al.21
Direct sequencing
To identify mutations of the KRAS and EGFR genes, 
polymerase chain reaction (PCR) analysis was per-
formed. The oligonucleotide primers for EGFR exon 
18−21 and KRAS exons 2 and 3 were used (Table 1). 
Briefly, the PCR amplification of DNA samples (20 ng) 
was carried out in a 50-μL reaction volume with a 
final concentration of 1X PCR buffer (10 mmol/L 
Tris-HCl [pH 8.3], 1.5 mmol/L MgCl2, 50 mmol/L 
KCl, and 0.01% gelatin), 100 mmol/L deoxynucle-
otide triphosphate (Promega, Madison, WI, USA), and 
5 U (1 U/μL) of Biotools DNA polymerase (Biotools 
Biotechnological and Medical Laboratories, SA, 
Madrid, Spain) for each reaction. The PCR products 
were purified by the QIAEX II gel extraction kit 
(Qiagen Inc., Valencia, CA, USA) and then subjected 
to sequencing using a double-stranded cycle se-
quencing system (Gibco-BRL, Gaithersburg, MD, USA). 
The purified products were then sequenced directly 
with a T7 promoter/IRD800 (LI-COR, Lincoln, NE, 
USA), which was a T7 promoter primer labeled with 
a heptamethine cyanine dye (Table 1), or using DNA 
polymerase incorporating infrared fluorochrome-
labeled deoxyadenosine triphosphate for sequencing 
reaction. An automated DNA electrophoresis system 
(model 4200; LI-COR) with a laser diode emitting at 
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785 nm and fluorescence detection between 815 nm 
and 835 nm was used to detect and analyze the se-
quencing ladder. Following the loading of samples, 
electrophoresis was carried out at a constant voltage 
of 2000 V with the gel heated to 50ºC. Data collec-
tion and image analysis was performed using the 
Base Image IR software supplied with the model 
4200 DNA sequencer (LI-COR).
Total RNA isolation and complementary DNA 
(cDNA) synthesis
Total RNA was isolated from collected cancer tis-
sue specimens by the acid-guanidinium-phenol-
chloroform method according to standard protocol. 
The RNA concentration was determined spectropho-
tometrically, based on absorbance at 260 nm. First-
strand cDNA was synthesized from total RNA by using 
the Advantage RT-PCR kit (Promega). Reverse tran-
scription was performed in a reaction mixture con-
sisting of transcription optimized buffer, oligo(dT)15 
primer at 25 mg/mL 100mM PCR nucleotide mix, 
200mM Moloney murine leukemia virus (M-MLV) re-
verse transcriptase, and 25 μL of recombinant ribonu-
clease inhibitor. The reaction mixtures with RNA were 
incubated at 42ºC for 2 hours, heated to 95ºC for 
5 minutes, and then stored at 48ºC until the analysis.
Northern blot
Twenty micrograms of total RNA was denatured with 
6.5% formamide and 50% formaldehyde for 15 min-
utes at 55ºC and separated by electrophoresis through 
1.2% agarose gels containing 1.1% formaldehyde. 
Next, RNA was transferred to a nylon membrane 
(Schleicher & Schuell, Dassel, Germany) and fixed. 
The blots were successively hybridized with human 
EGFR cDNA. The hybridized filters were then washed 
twice with washing buffer (Solution I: 3X saline sodium 
citrate, 0.5% sodium dodecyl sulfate; Solution II: 0.5X 
saline sodium citrate, 0.1% sodium dodecyl sulfate) 
at 65ºC to wash off the unbound probe. The mem-
brane was exposed to Kodak X-film at −70ºC for 
autoradiography. We used β-actin signal to normalize 
data for the above messenger RNA (mRNA). All of 
the probes were confirmed by direct sequencing.
Statistical analysis
All data were analyzed using the Statistical Package 
for the Social Sciences version 11.5 (SPSS Inc., 
Chicago, IL, USA). The χ2 test was used to analyze 
the correlation between membrane array results 
and the clinicopathologic features of NSCLC pa-
tients. A p value of less than 0.05 was considered 
to be statistically significant.
Results
Of the 180 lung cancer tissue samples analyzed, 
KRAS mutations were found in 28 samples, includ-
ing 15 cases of codon 12, seven cases of codon 13, 
four cases of codon 15, one case of codon 31, and 
one case of codon 61. In the EGFR mutation analy-
sis, 33 cases of mutation in exon 18−20 were found, 
including G719C, E709K, E709A and N700D of exon 
18, deletion of L747-T751 of exon 19, and V769M, 
S768I and R803W of exon 20. Moreover, hot spot 
mutations were concentrated at 18G719C and 
18E709K (Table 2). The sequencing of KRAS codon 
12 is shown in Figure 1, which illustrates the muta-
tion of case 15 from GGT to GTT.
The occurrence of EGFR overexpression in the 
tissue samples was 25% (46 cases; Table 3). The ratio 
of simultaneous mutation was 65% (29/46). Figure 2 
shows the result of Northern blot analysis using 
EGFR mRNA. The figure shows that in the tissue 
sample of Case 6, the EGFR mRNA does not have 
Table 1 Nucleotide sequences of primers used for polymerase chain reaction (PCR) and DNA sequencing
 Sequences PCR 
Gene
 
Exon
 Forward primer Reverse primer product (bp)
EGFR 18 GCTGAGGTGACCCTTGTCTC ACAGCTTGCAAGGACTCTGG 246
EGFR 19 CCCAGTGTCCCTCACCTTC CCACACAGCAAAGCAGAAAC 239
EGFR 20 TTCTGGCCACCATGCGA CCGTATCTCCCTTCCCTGATTA 258
EGFR 21 TGATCTGTCCCTCACAGCAG TCAGGAAAATGCTGGCTGAC 231
KRAS  2 5-TAATACGACTCACTATAGGGAGA 5-TCCTAGGTCAGCGCAACCAAAT-3 131
   TATGTTGAGGGCCCATCTCTC-3
KRAS  3 5-TAATACGACTCACTATAGGGTT 5-CACAAAGAAAGCCCTCCCCA-3 148
   CCTACAGGAAGCAAGTAG-3
Sequencing 5-CCCTATAGTGAGTCGTATTA-3
primer
EGFR: epidermal growth factor receptor.
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apparent transition expression after correction with 
β-actin. However, the mRNA expression in Case 7 
was several times greater.
In the 28 KRAS mutations, only two cases had 
coexisting EGFR mutations (Table 4); none had co-
existing overexpression of EGFR (Table 5).
After a statistical analysis, despite the alter-
ations of KRAS or EGFR and the clinical mani-
festations of patients, no statistically significant 
relationships were found in sex, size of tumor, metas-
tasis, and on metastasis status (Table 6). Neverthe-
less, there was a significant correlation between 
Table 2 Mutational analysis of epidermal growth factor receptor (EGFR) and KRAS
Gene Nucleotide alteration Amino acid alteration Frequency (%) Total
KRAS    
 Codon 12 GGT  GTT G12V 15 (53.57) 
 Codon 13  GGC  GCC G13A 7 (25) 
 Codon 15 GGC  GCC G15A 4 (14.29) 
 Codon 31 GAA  CAA E31Q 1 (3.57) 
 Codon 61 CAA  CTA Q61L 1 (3.57) 
 Total    28
EGFR    
 Exon 18 2344A > G N700D 4 (12.12) 
 2371G > A E709K 7 (21.21) 
 2372A > C E709A 1 (3.03) 
 2401G > T G719C 8 (24.24) 20 (60.61)
 Exon 19 2486_2500del delL747-T751 3 (9.09) 3 (9.09)
 Exon 20 2549G > T S768I 2 (6.06) 
 2551G > A V769M 4 (12.12) 
 2653C > T R803W 4 (12.12) 10 (30.3)
 Total    33
Case 15 (M)
Codon 12
G(G/T) T
Case 16 (WT)
A T C G A T C G
Figure 1 Sequencing analysis of KRAS codon 12 in non-
small cell lung carcinoma patients. Case 16 is wild-type 
(WT) and case 15 had a mutated (M) codon 12 from GGT 
to GTT.
Table 3  Correlation between epidermal growth factor 
receptor (EGFR) overexpression and EGFR 
mutation in lung cancer tissues
EGFR EGFR mutation
overexpression Wild-type Mutation 
Total
 
p
Negative 130 4 134 < 0.001
Positive 17 29 46
Total 147 33 180
0.0
0.001 
Re
la
ti
o
n
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f m
RN
A
 
N 
0.008 
0.9 
Case 6 Case 7
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
1.0
N Case 6 Case 7
EGFR 
β-actin
Figure 2 Northern blot analysis of epidermal growth 
factor receptor (EGFR) messenger RNA expression in 
samples of lung cancer patients. EGFR messenger RNA 
was significantly overexpressed in Cases 6 and 7 com-
pared with normal tissues after calibrating with β-actin 
expression. N: normal tissues.
KRAS mutation is correlated with EGFR in NSCLC 69
KRAS mutations in cancer tissue and EGFR presence 
or overexpression.
Discussion
The results showed that the proportion of EGFR mu-
tations in lung cancer patients in Taiwan is similar 
to that in other Asian countries, such as Japan and 
Korea, which is approximately 25%.14,22 However, 
this ratio is different in Western countries, which 
is generally around 50%.13,23 Nevertheless, no sig-
nificant differences were found in Eastern and 
Western countries in terms of EGFR overexpression.24
There was no significant relationship between 
KRAS mutations and patients’ clinical manifestations. 
Table 5  Correlation between KRAS mutation and epider-
mal growth factor receptor (EGFR) overexpres-
sion in lung cancer tissues
 EGFR overexpression
KRAS mutation
 Negative Positive 
Total p
Wild-type 106 46 152 0.001 
Mutation 28 0 28 
Total 134 46 180 
Table 4  Correlation between KRAS and epidermal growth 
factor receptor (EGFR) mutations in lung cancer 
tissues
 EGFR mutation
KRAS mutation
 Wild-type Mutation 
Total p
Wild-type 121 31 152 0.10
Mutation 26 2 28 
Total 147 33 180 
Table 6  Correlation between KRAS and epidermal growth factor receptor (EGFR) genetic mutations in lung cancer 
tissues and patients’ clinical manifestations
 KRAS mutation EGFR overexpression EGFR mutation
 Wild-type Mutation p Negative Positive p Wild-type Mutation p
 152 28  134 46  147 33
Sex     
 Unknown 1 0 0.762 1 0 0.802 1 0 0.81
 Female 74 12  63 23  69 17
 Male 77 16  70 23  77 16
Smoking history     
 Nonsmoker 102 14 0.082 90 26 0.193 95 21 0.92
 Smoker 50 14  44 20  52 12
Histology
 Adenocarcinoma 116 19 0.222 101 34 0.905 111 24 0.63
 Adenosquamous carcinoma 6 0  4 2  4 2
 Squamous cell carcinoma 30 9  29 10  32 7
TNM stage
 I 46 8 0.931 36 18 0.177 42 12 0.64
 II 17 3  17 3  18 2
 III 44 7  42 9  41 10
 IV 45 10  39 16  46 9
Tumor size (T)      
 T1 40 6 0.375 30 16 0.296 37 9 0.98
 T2 64 15  61 18  64 15
 T3 28 2  25 5  25 5
 T4 20 5  18 7  21 4
Lymph node (N)      
 N0 70 11 0.118 56 25 0.323 65 16 0.84
 N1 20 5  20 5  22 3
 N2 42 4  34 12  37 9
 N3 20 8  24 4  23 5
Metastasis (M)      
 M0 107 18 0.519 95 30 0.471 102 23 0.97
 M1 45 10  39 16  45 10
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Our results differ from those of many other pub-
lished studies that suggest KRAS to be a factor in 
the early stage or prognosis of lung cancer.25,26 The 
main cause of this difference may be the lack of 
distinction between smokers and non-smokers in 
this study. In our previous paper on KRAS, the im-
plications of this omission were discussed in de-
tail.27 Even though EGFR overexpression was highly 
correlated with the clinical disease progress of 
colorectal cancer, it was not found in lung cancer 
patients.28 The conclusion was the same as in Wang’s 
study.29 This may be caused by the different forma-
tions of cancer.
Kosaka et al20 showed that the KRAS and EGFR 
mutations cannot coexist in lung cancer tissues. 
The result of our study unanimously reconfirmed 
this finding, and is the first to discover similar 
relationships between KRAS mutation and EGFR 
overexpression. Although there were very few ex-
ceptions, the trend was significantly correlated 
between the study groups. This result was consis-
tent with the findings of Marchetti et al30 in that 
patients with EGFR mutations are prone to gene 
amplification (since gene mutations and amplifica-
tion play an important role in EGFR overexpres-
sion31). In analyzing the evaluation of therapeutic 
targets for lung cancer, Han et al32 suggested that 
it may be necessary to combine KRAS and EGFR 
mutations in analysis because of their correlation. 
Therefore, probing into any single factor in isolation 
may cause inaccuracy in the evaluation of tumor 
formation or the efficacy of EGFR tyrosine kinase 
inhibitor on therapeutic targets of lung cancer.
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